Company developing compounds to treat schizophrenia, other nervous system disorders
Promentis Pharmaceuticals Inc., a Milwaukee company developing compounds for the treatment of schizophrenia and other central nervous system disorders, has raised $8.7 million in equity funding, according to a filing with federal securities regulators.
The company raised the funds from eight investors. The funding round was launched Sept. 21 and has been completed with a total amount raised of $8,787,399, according to the document. Promentis raised nearly $3 million in early 2014 in a series B financing round.
The funding is another in a string of venture capital investments in Wisconsin start-ups that have been disclosed in the last three weeks. During that time, Promentis and five other health-related companies have told the U.S. Securities and Exchange Commission that they’ve raised a total of nearly $30 million.